BE1001973A5 - Expression et purification d'une proteine du gene htlv-iii gag/env. - Google Patents

Expression et purification d'une proteine du gene htlv-iii gag/env. Download PDF

Info

Publication number
BE1001973A5
BE1001973A5 BE8700350A BE8700350A BE1001973A5 BE 1001973 A5 BE1001973 A5 BE 1001973A5 BE 8700350 A BE8700350 A BE 8700350A BE 8700350 A BE8700350 A BE 8700350A BE 1001973 A5 BE1001973 A5 BE 1001973A5
Authority
BE
Belgium
Prior art keywords
protein
htlv
expression
gag
iii
Prior art date
Application number
BE8700350A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of BE1001973A5 publication Critical patent/BE1001973A5/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/974—Aids related test
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Méthodes et compositions pour le clonage et l'expression de plasmides portant des gènes codant pour une nouvelle protéine dérivée de HTLV-III. Cette protéine, qui est appelée protéine gag/env et qui contient des déterminants antigéniques à la fois des protéines de la particule centrale et de l'enveloppe du HTLV-III, peut être purifiée jusqu'à l'état homogène et utilisée comme base pour des tests diagnostiques pour la détection de la présence d'anticorps dirigés contre les virus associés au SIDA ou des virus eux-mêmes dans les sérums humains et d'autres liquides biologiques. La protéine gag/env peut également être préparée pour être utilisée comme vaccin pour la protection contre le SIDA par immunisation préventive.
BE8700350A 1986-04-04 1987-04-03 Expression et purification d'une proteine du gene htlv-iii gag/env. BE1001973A5 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/848,671 US4925784A (en) 1986-04-04 1986-04-04 Expression and purification of an HTLV-III gag/env gene protein

Publications (1)

Publication Number Publication Date
BE1001973A5 true BE1001973A5 (fr) 1990-05-02

Family

ID=25303966

Family Applications (1)

Application Number Title Priority Date Filing Date
BE8700350A BE1001973A5 (fr) 1986-04-04 1987-04-03 Expression et purification d'une proteine du gene htlv-iii gag/env.

Country Status (23)

Country Link
US (1) US4925784A (fr)
JP (1) JP2625118B2 (fr)
KR (1) KR930001118B1 (fr)
AT (1) AT400442B (fr)
AU (1) AU599091B2 (fr)
BE (1) BE1001973A5 (fr)
BR (1) BR8701528A (fr)
CA (1) CA1341249C (fr)
CH (1) CH676004A5 (fr)
DE (3) DE3744825C2 (fr)
DK (1) DK172274B1 (fr)
ES (3) ES2004133A6 (fr)
FR (1) FR2606422B1 (fr)
GB (1) GB2188639B (fr)
IL (1) IL82088A (fr)
IT (1) IT1203851B (fr)
NL (1) NL192275C (fr)
NO (1) NO871409L (fr)
NZ (1) NZ219837A (fr)
SE (1) SE8701413L (fr)
SG (1) SG102792G (fr)
SU (1) SU1644720A3 (fr)
ZA (1) ZA871724B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9309574B1 (en) 1984-08-22 2016-04-12 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Molecular cloning of HIV-1 from immortalized cell lines
DE3688051T2 (de) * 1985-12-17 1993-06-24 Akzo Nv Immunochemisches reagenz.
WO1987003908A1 (fr) * 1985-12-24 1987-07-02 United States Of America, Represented By The Unite Clones de plasmides et de phages du virus lymphotrope des cellules t humaines de type iii
US4925784A (en) * 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
US4983387A (en) * 1986-05-19 1991-01-08 Viral Technologies Inc. HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus
US5142025A (en) * 1986-08-01 1992-08-25 Repligen Corporation Recombinant HTLV-III proteins and uses thereof
US5166050A (en) * 1986-08-20 1992-11-24 Bristol-Myers Squibb Company Monoclonal antibodies and peptides useful in treating and diagnosing HIV infections
NZ221440A (en) * 1986-08-20 1991-11-26 Genetic Systems Corp Composition containing monoclonal antibodies/peptides useful in treating and diagnosing hiv infections
US5041385A (en) * 1986-11-01 1991-08-20 Oxford Gene Systems Limited Vector expressing fusion proteins and particles
EP0287226A1 (fr) * 1987-03-23 1988-10-19 Hiver Limited Vaccin
PT88416B (pt) * 1987-09-04 1992-10-30 Wellcome Found Processo para determinacao imunologica de anticorpos e processo para a preparacao de uma proteina com capacidade de ligacao a anticorpos e de composicoes farmaceuticas que a contem
NO881501L (no) * 1987-10-09 1989-04-10 Repligen Corp Rekombinante htlv-111-proteiner og anvendelser av disse.
EP0311228A3 (fr) * 1987-10-09 1990-05-02 Repligen Corporation Polypeptides recombinants et leur utilisation, y compris un diagnostic pour le virus du SIDA
DE3879881D1 (de) * 1987-11-16 1993-05-06 Hoffmann La Roche Rekombinante hiv-2 polypeptide.
US5780038A (en) * 1987-11-16 1998-07-14 Roche Diagnostic Systems, Inc. HIV-2 envelope polypeptides
JPH01179687A (ja) * 1987-12-30 1989-07-17 Chemo Sero Therapeut Res Inst Ｈｉｖ融合蛋白質
JP2559482B2 (ja) * 1988-01-12 1996-12-04 ジーンラブズ テクノロジーズ，インコーポレイテッド Ｈｔｌｖーｉペプチド抗原および分析法
EP0343132B1 (fr) * 1988-05-06 1994-08-17 Ferropas Ag Procédés et méthodes de production d'antigènes HIV
US5204259A (en) * 1988-05-06 1993-04-20 Pharmacia Genetic Engineering, Inc. Methods and systems for producing HIV antigens
FR2632310B1 (fr) * 1988-06-06 1992-04-10 Pasteur Institut Peptides ayant des proprietes protectrices d'un virus pathogene du type hiv dans des cellules sensibles
US6197496B1 (en) * 1988-06-09 2001-03-06 Institut Pasteur Immunological reagents and diagnostic methods for the detection of human immunodeficiency virus type 2 utilizing multimeric forms of the envelope proteins gp300, p200, and p90/80
CA2003383A1 (fr) 1988-11-23 1990-05-23 Sushil G. Devare Antigenes de hiv recombinants derives d'adn synthetique
US5817318A (en) * 1989-05-03 1998-10-06 Connaught Laboratories Limited Synthetic peptides for an HIV-1 vaccine
GB8923123D0 (en) * 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
EP0449116B2 (fr) * 1990-03-21 2004-08-25 Geneart GmbH Séquences d'ADN codant pour des polypeptides rétroviraux modifiés et vaccins les contenant ou aggrégats de ceux-ci
US6228608B1 (en) 1991-02-28 2001-05-08 Aquila Biopharmaceuticals, Inc. Recombinant FIV glycoprotein 160 and P24 gag protein
WO1993004087A1 (fr) * 1991-08-21 1993-03-04 Abbott Laboratories Depistage de l'hepatite c a l'aide d'antigenes recombines diriges contre la region c-100
GB9208218D0 (en) * 1992-04-14 1992-05-27 British Bio Technology Hybrid particles
DE69231705T2 (de) * 1992-06-04 2001-10-18 Univ Osaka Res Found Gag-Env Fusion-Antigen aus HIV
KR0172970B1 (ko) * 1992-06-17 1999-02-01 김영길 Aids백신에 유용한 키메릭 단백 및 그의 제조방법
US5580773A (en) * 1992-06-17 1996-12-03 Korea Green Cross Corporation Chimeric immunogenic gag-V3 virus-like particles of the human immunodeficiency virus (HIV)
DK0586076T3 (da) * 1992-08-07 2003-10-20 Wyeth Corp Rekombinant adenovirus-vacciner
CN1111540C (zh) * 1993-06-09 2003-06-18 康诺特实验室有限公司 串联的合成hiv－1肽类
SG43029A1 (en) * 1993-08-11 1997-10-17 American Home Prod Recombinant adenovirus vaccines
US6025141A (en) * 1993-12-10 2000-02-15 The Canadian Red Cross Society Immunofluorescence assay for the detection of antibodies using recombinant antigens in insoluble form
DE4405810A1 (de) 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
WO1995032000A1 (fr) * 1994-05-20 1995-11-30 Microgenesys, Inc. Immunogenes de polyproteines de vih
FR2726576B1 (fr) * 1994-11-07 1997-01-31 Pf Medicament Production de peptides analogues de peptides hydrophobes, peptide recombinant, sequence d'adn correspondante
US6846905B2 (en) 1997-08-15 2005-01-25 Abbott Laboratories Antigen constructs useful in the detection and differentiation of antibodies to HIV
NO311807B1 (no) 1999-03-04 2002-01-28 Bionor Immuno As HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV
DE10106295C1 (de) * 2001-02-02 2002-08-22 Gaifar German American Inst Fo Protein mit mehreren Antigen-Epitop-Sequenzen, welches immobilisiert ist
US10335482B2 (en) 2012-06-06 2019-07-02 Bionor Immuno As Method of inducing an anti-HIV-1 immune response comprising administering a C5/TM-GP41 peptide dimer
WO2016005508A1 (fr) 2014-07-11 2016-01-14 Bionor Immuno As Procédé permettant de réduire et/ou de retarder les effets pathologiques du virus de l'immunodéficience humaine i (vih) ou de réduire le risque de développer le syndrome d'immunodéficience acquise (sida)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0270114A2 (fr) * 1986-12-05 1988-06-08 F. Hoffmann-La Roche Ag Polypeptides ENV/GAG

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237224A (en) * 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
DE2814039C3 (de) * 1978-03-31 1981-02-19 Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf), 3300 Braunschweig Verfahren zur Herstellung von Hybrid-Bakterien
GB8324800D0 (en) * 1983-09-15 1983-10-19 Pasteur Institut Antigens
GB8423659D0 (en) * 1984-09-19 1984-10-24 Pasteur Institut Cloned dna sequences
NZ228756A (en) * 1984-04-23 1990-10-26 Us Health Detection of hiv antigen using competition immune assay or western blot assay
EP0188574A1 (fr) * 1984-07-20 1986-07-30 Worcester Foundation For Experimental Biology Vaccins et vecteurs retroviraux, et methodes pour leur construction
IL76082A (en) * 1984-08-22 1991-07-18 Us Health Molecular clones of the genome of htlv-iii and a process for the preparation thereof
CA1340878C (fr) * 1984-10-26 2000-01-25 Takis S. Papas Production bacterienne de fragments de proteine de l'enveloppe du retrovirus de la leucemie (lymphotropique) des cellules t de l'humain (htlu-i), que son usage dans le depisage seroepidemiologique de tumeurs malignes lymphatiques chez les humains
CA1341482C (fr) * 1984-10-31 2005-05-10 Paul A. Luciw Procede de preparation de fragments de retrovirus du groupe du sida
DE3588134T2 (de) * 1984-12-24 1997-03-20 Genentech Inc Fusionen von AIDS-verwandten Polypeptiden
US4774175A (en) * 1985-03-01 1988-09-27 Centocor, Inc. Immunochemical methods for the detection of antibody against HTLV-III
US4751180A (en) * 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
GR860915B (en) * 1985-04-08 1986-07-11 Genetic Systems Corp Expression and diagnostic use of gag encoded peptides which are immunologically reactive with antibodies to lav
NZ215867A (en) * 1985-04-19 1989-10-27 Hoffmann La Roche Aids envelope protein, dna vectors and method of production
DE3650175T3 (de) * 1985-04-29 2007-09-06 Bio-Rad Laboratories, Inc., Hercules Synthetische antigene zum nachweis von aids.
EP0213894A3 (fr) * 1985-08-23 1987-10-21 Advanced Genetics Research Institute Vaccins à particules virales imparfaites et méthodes d'utilisation
JP2564268B2 (ja) * 1985-08-28 1996-12-18 協和醗酵工業株式会社 融合抗原ポリペプチド
JP2702911B2 (ja) * 1985-09-11 1998-01-26 ユナイテツド・バイオメデイカル・インコ−ポレ−テツド 合成ペプチド、並びにそれを用いたエイズおよびプリ・エイズの検出方法
GR862412B (en) * 1985-09-25 1987-01-23 Oncogen Vaccines and immuinoassays for acquired immune deficiency syndrome
GB8525615D0 (en) * 1985-10-17 1985-11-20 Hoffmann La Roche Polypeptides
WO1987002775A1 (fr) * 1985-10-24 1987-05-07 Southwest Foundation For Biomedical Research Peptides synthetiques et leur utilisation pour le diagnostic et la vaccination contre le sida et son complexe associe
JPS62164696A (ja) * 1986-01-06 1987-07-21 エフ．ホフマン　―　ラ　ロシュ　アーゲー ＨＴＬＶ−３ｇａｇ遺伝子の発現
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
US4753873A (en) * 1986-02-03 1988-06-28 Cambridge Bioscience Corporation Peptides for the diagnosis of HTLV-III antibodies, their preparation and use
US4808536A (en) * 1986-02-27 1989-02-28 Centocor, Inc. Immunochemical method for detection of antibody against HTLV-III core protein based upon recombinant HTLV-III gag gene encoded protein
US4925784A (en) * 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0270114A2 (fr) * 1986-12-05 1988-06-08 F. Hoffmann-La Roche Ag Polypeptides ENV/GAG

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANALYTICAL BIOCHEMISTRY, vol. 161, no. 2, mars 1987, pages 370-379, Academic Press Inc.; R.L. SHOEMAN et al.: "Comparison of recombinant human immunodeficiency virus gag precursor and gag/env fusion proteins and a synthetic env peptide as diagnostic reagents" *
BIO/TECHNOLOGY, vol. 4, no. 2, février 1986, pages 128-133; C.D. CABRADILLA et al.: "Serodiagnosis of antibodies to the human aids retrovirus with a bacterially synthesized ENV polypeptide" *

Also Published As

Publication number Publication date
SG102792G (en) 1993-01-29
DE3744825C2 (fr) 1990-10-25
DK172274B1 (da) 1998-02-16
FR2606422B1 (fr) 1991-01-04
IL82088A (en) 1991-11-21
IT1203851B (it) 1989-02-23
NO871409D0 (no) 1987-04-03
DE3744827C2 (fr) 1990-08-09
ES2004133A6 (es) 1988-12-01
FR2606422A1 (fr) 1988-05-13
ES2009350A6 (es) 1989-09-16
JPS62244393A (ja) 1987-10-24
AT400442B (de) 1995-12-27
SU1644720A3 (ru) 1991-04-23
ES2016426A6 (es) 1990-11-01
JP2625118B2 (ja) 1997-07-02
DK166087A (da) 1987-10-05
ZA871724B (en) 1987-11-25
SE8701413D0 (sv) 1987-04-03
NL8700795A (nl) 1987-11-02
BR8701528A (pt) 1988-01-19
KR930001118B1 (ko) 1993-02-18
NL192275B (nl) 1996-12-02
GB2188639A (en) 1987-10-07
IT8719973A0 (it) 1987-04-03
AU7103287A (en) 1987-10-08
GB2188639B (en) 1990-09-26
DK166087D0 (da) 1987-04-01
SE8701413L (sv) 1987-10-05
ATA82487A (de) 1995-05-15
NL192275C (nl) 1997-04-03
AU599091B2 (en) 1990-07-12
CA1341249C (fr) 2001-06-12
CH676004A5 (fr) 1990-11-30
NZ219837A (en) 1990-09-26
US4925784A (en) 1990-05-15
IL82088A0 (en) 1987-10-30
DE3711016A1 (de) 1987-10-08
KR870010189A (ko) 1987-11-30
GB8707971D0 (en) 1987-05-07
NO871409L (no) 1987-10-05
DE3711016C2 (fr) 1990-08-02

Similar Documents

Publication Publication Date Title
BE1001973A5 (fr) Expression et purification d'une proteine du gene htlv-iii gag/env.
Hu et al. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160
Kan et al. Identification of HTLV-III/LAV sor gene product and detection of antibodies in human sera
Zarling et al. Proliferative and cytotoxic T cells to AIDS virus glycoproteins in chimpanzees immunized with a recombinant vaccinia virus expressing AIDS virus envelope glycoproteins.
Zarling et al. T-cell responses to human AIDS virus in macaques immunized with recombinant vaccinia viruses
Fechner et al. Provirus variants of the bovine leukemia virus and their relation to the serological status of naturally infected cattle
Kettmann et al. Bovine leukemia virus
Miller et al. The gag-specific cytotoxic T lymphocytes in rhesus monkeys infected with the simian immunodeficiency virus of macaques.
AU771827B2 (en) HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
US5985641A (en) Non-infectious, replication-impaired, immunogenic human immunodeficiency virus type 1 retrovirus-like particles with multiple genetic deficiencies
US5030449A (en) Synthetic vaccine against AIDS virus
PT91881A (pt) Processo para a preparacao de novas proteinas e peptideos de hiv uteis no diagnostico, profilaxia ou terapia da sida
JP2011219481A (ja) Ｈｉｖペプチド、抗原、ワクチン組成物、ｈｉｖにより誘発される抗体を検出するためのイムノアッセイキット及び方法
JPH08500965A (ja) ハイブリッドウイルス発現ベクター，その使用および新規アッセイ
Cabradilla et al. Serodiagnosis of antibodies to the human AIDS retrovirus with a bacterially synthesized env polypeptide
AU737857B2 (en) Non-M, non-O HIV-1 strains, fragments and uses
CA2304125A1 (fr) Materiau genetique sous forme de cassettes d'immunisation a base d'adn de vif attenue pour des vaccins genetiques
Nardelli et al. Cellular immune responses induced by in vivo priming with a lipid-conjugated multimeric antigen peptide.
Nicot et al. Establishment of HTLV-I-infected cell lines from French, Guianese and West Indian patients and isolation of a proviral clone producing viral particles
Kos et al. Induction of primary anti‐viral cytotoxic T cells by in vitro stimulation with short synthetic peptide and interleukin‐7
Dobrescu et al. Human immunodeficiency virus 1 reservoir in CD4+ T cells is restricted to certain V beta subsets.
Dittmer et al. Different immunological requirements for protection against acute versus persistent Friend retrovirus infections
Beier et al. Establishment of a new bovine leukosis virus producing cell line
Vogel et al. Induction of anti-simian immunodeficiency virus cellular and humoral immune responses in rhesus macaques by peptide immunogens: correlation of CTL activity and reduction of cell-associated but not plasma virus load following challenge
Perrin et al. Interleukin-2 production in vitro: a new approach to the study of rabies vaccine immunogenicity as appraised by testing different glycoprotein presentations

Legal Events

Date Code Title Description
RE Patent lapsed

Effective date: 20030430